Category CRISPR
CASGEVY: Rethinking Drug Costs Through the Lens of Public Access
Maria Klimenko considers the extent to which the price of innovative treatments like CASGEVY, a type of gene therapy, should reflect not just the cost of development, but also their broader societal impact — and the public healthcare system’s ability to provide equitable access.
Relational Autonomy & Public Funding for Noninvasive Prenatal Testing
Biplab Kumar Halder shares how a relational autonomy framework informed his research regarding public funding of Noninvasive Prenatal Testing (NIPT).
Polygenic Risk Scores to Select Embryos: A Need for Societal Debate
Hazar Haidar discusses the need for a societal debate to explore challenges related to polygenic embryo screening.
Heritable Human Genome Editing? It May Never Be Safe
Katie Hasson recounts the recent failures to edit the human genome.
Prison sentence for creator of first CRISPR babies
Françoise Baylis calls for a critical analysis of the institutional context that contributed to the actions for which He Jiankui has been sentenced to prison.
Impact Ethics 